Table 1.

Comparison of clinical and microbiological characteristics between immunosuppressed and non-immunosuppressed patients with imported strongyloidiasis in +REDIVI (2009–2017)

	Immunosuppressed patients (n = 80)	Non-immunosuppressed patients (n = 160)	P-value
Presence of symptoms Severe clinical manifestations Presence of eosinophilia Eosinophil cell count a, cells/mm3 Positive Ritchie’s formalin-ether technique Positive fecal culture Positive S. stercoralis serology Serological OD value b Confirmed diagnosis Number of cured patients Number of patients with treatment success c Number of deaths	19/80 (23.8%) 3/80 (3.8%) 34/65 (52.3%) 870 (590–1600) 8/65 (12.3%) 11/52 (21.1%) 63/66 (95.4%) 2.8 (1.4–6.2) 13/68 (19.1%) 24/61 (39.3%) 42/61 (68.9%) 0/80 (0%)	32/160 (20%) 0/160 (0%) 106/135 (78.5%) 990 (600–1400) 14/129 (10.9%) 32/94 (34%) 131/132 (99.2%) 3.4 (1.8–6) 35/135 (25.9%) 46/119 (38.7%) 80/119 (67.2%) 0/160 (0%)	0.503 0.036 <0.001 0.719 0.763 0.102 0.109 0.398 0.281 0.929 0.825-

Data are reported as number (%) of patients or median (IQR).

^aOnly in patients with eosinophilia.

^bOnly patients in whom the SciMedx serology was performed were analyzed.

^cTreatment success includes cure and probable cure.